Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Letermovir for Secondary CMV Prophylaxis Post-Haplo-HSCT
NCT05914701Phase 4Unknown
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Jul 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules
01
Overview
A Phase 4 trial of letermovir in cytomegalovirus infection (CMV), sponsored by Institute of Hematology and Blood Diseases Hospital. Status: unknown.
02
Drugs
letermovir
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT05914701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05914701.